Compare SHPH & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHPH | DSS |
|---|---|---|
| Founded | 2012 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.3M |
| IPO Year | 2022 | 2020 |
| Metric | SHPH | DSS |
|---|---|---|
| Price | $0.57 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 82.3K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,085,000.00 |
| Revenue This Year | N/A | $1.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.50 |
| 52 Week High | $5.59 | $1.90 |
| Indicator | SHPH | DSS |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 30.94 |
| Support Level | $0.50 | N/A |
| Resistance Level | $1.17 | $1.04 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 12.07 | 9.69 |
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
DSS Inc is operating a business focused on four operating segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. Currently operates five distinct business lines that operate around the globe with primary operations in North America and Asia. Product packaging manufactures and sells sophisticated custom folding cartons, mailers, photo sleeves, and complex three-dimensional direct mail solutions. The biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the Securities and Investment Management.